Mingdong Zhou

Dr. Zhou is the founder & CEO of Zensun. Dr. Zhou earned his B.S. in biology from Fudan University in 1982 and his Ph.D. in cellular and molecular biology from New York State University in 1992. After he completed postdoctoral research training at the University of California, San Diego in 1996, he moved to Sydney, Australia, where he headed the Cell Signaling Laboratory of the Victor Chang Cardiac Research Institute. He discovered the important effects of neuregulins in maintaining cardiomyocyte structure and function, as well as the fact that ErbB2/ErbB3 heterodimerization is essential for tumor development. Dr. Zhou has authored more than 30 original research papers in PNAS, JACC, JBC, Circulation Research, and other international journals. He has applied for 203 patents, 85 of which have been granted, including 67 worldwide and 18 patents in China. In 2000, Dr. Zhou returned to China and founded Zensun (Shanghai) Sci. & Tech. Co., Ltd. Zensun focuses on leading-edge research and development of mechanism-based healthcare solutions. The current pipeline includes cardiovascular disease treatment, anti-cancer drugs, and treatments for energy metabolism disorders. The first-in-class drug Neucardin™, which addresses wholly innovative targets and mechanisms, is now in phase III clinical trials and will bring revolutionary innovations in cardiomyocyte therapy. After more than ten years of research and development, Zensun’s product line of innovative drugs and medical instruments with short, medium, or long-term horizons for commercialization is ready to begin appearing in the global market, and Zensun will become an integrated company doing research, production, and sales.